NCT00244816 2025-10-23
Taxoprexin® Treatment for Advanced Eye Melanoma
American Regent, Inc.
Phase 2 Completed
Clinical Trials
7 trialsNCT00422877 2025-10-16
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
American Regent, Inc.
Phase 2 Terminated
NCT00249262 2025-09-26
Taxoprexin Treatment for Advanced Skin Melanoma
American Regent, Inc.
Phase 2 Completed
NCT00243867 2025-08-01
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
American Regent, Inc.
Phase 3 Completed
NCT00087776 2025-07-23
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
American Regent, Inc.
Phase 3 Terminated
NCT03806426 2024-04-25
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
S.L.A. Pharma AG
Phase 3 Active not recruiting
NCT00146211 2007-12-27
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
Amarin Neuroscience Ltd
Phase 3 Completed